Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610091 | 1.00 | DPP3 (0.69) | DPP3OPRM1OPRD1OPRK1NTSR2 | |
| SCHEMBL29974089 | 0.97 | DPP3 (0.66) | DPP3OPRM1OPRD1OPRK1 | |
| SCHEMBL29772686 | 0.96 | DPP3 (0.65) | DPP3OPRM1 | |
| SCHEMBL29577213 | 0.96 | DPP3 (0.65) | DPP3OPRM1 | |
| SCHEMBL30050936 | 0.96 | DPP3 (0.69) | DPP3OPRM1 | |
| SCHEMBL31072081 | 0.95 | DPP3 (0.68) | DPP3OPRM1NTSR2NTSR1SORT1 | |
| SCHEMBL29963309 | 0.95 | DPP3 (0.64) | DPP3OPRM1NTSR2NTSR1SORT1 | |
| SCHEMBL30052255 | 0.94 | DPP3 (0.69) | DPP3OPRM1OPRD1OPRK1 | |
| SCHEMBL30957019 | 0.93 | DPP3 (0.61) | DPP3OPRM1OPRD1OPRK1NTSR2 | |
| SCHEMBL29842186 | 0.92 | DPP3 (0.65) | DPP3NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110430889-B | Macrocyclic peptides that reduce C-MYC protein levels and slow cancer cell growth | 堪萨斯大学 | 2023-09-19 | — | — | CN | claimed |
| CN-110430889-B | Macrocyclic peptides that reduce C-MYC protein levels and slow cancer cell growth | 堪萨斯大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-110430889-B | Macrocyclic peptides that reduce C-MYC protein levels and slow cancer cell growth | 堪萨斯大学 | 2023-09-19 | — | — | CN | disclosed |
| US-11325944-B2 | Macrocyclic peptides and derivatives thereof with opioid activity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325944-B2 | Macrocyclic peptides and derivatives thereof with opioid activity | OPRL1, OPRM1, OPRK1 | DPP3 333/4885OPRM1 2/4885OPRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.